Disclosed is a method for monitoring response to a treatment of at least one symptom of a pulmonary fibrotic disorder, the method comprising determining a level of LOXL2 in a sample of pulmonary tissue from a subject, wherein a decreased level of LOXL2 in the sample from the subject, compared to a control sample, indicates an amelioration of the at least one symptom of the pulmonary fibrotic disorder in the subject, wherein the symptom is an increase in pulmonary leukocyte number in the subject.
